Company news
Anatara Lifesciences Ltd (ASX:ANR) news
Every Anatara Lifesciences Ltd press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Appendix 4E & Financial Report 30 June 2026
August 18, 2026
Appendix 4D & Half Year Report 31 December 2025
February 25, 2026
Company Update
February 18, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Anatara receives firm commitments for $1.2m Placement
October 1, 2025
Trading Halt
September 28, 2025
Response to ASX Price Query
September 5, 2025
Pause in Trading
September 5, 2025
Appendix 4E & Financial Report 30 June 2025
August 13, 2025
Anatara receives $969,455 in R&D Tax Incentive for FY25
July 28, 2025
Hong Kong Patent Granted for GaRP
May 19, 2025
Phase II GaRP-IBS Trial Internal Analyses of Data Subsets
May 15, 2025
Funding Advance on R&D Refund
April 30, 2025
Phase II GaRP-IBS Trial Headline Analysis of Results
April 17, 2025
Phase II GaRP-IBS Trial & Anti-Obesity Project Updates
March 9, 2025
Appendix 4D & Half Year Report 31 December 2024
February 25, 2025
Australian Patent Granted for GaRP Product
January 28, 2025
GaRP-IBS Clinical Trial Update
December 12, 2024
Share Purchase Plan Offer Booklet
November 26, 2024
Successful Placement of $660k and Share Purchase Plan
November 15, 2024
Chair's Address to Shareholders
November 14, 2024
Appendix 4C & Q1 FY25 Activities Report
October 31, 2024
GaRP-IBS Irritable Bowel Syndrome Clinical Trial Update
October 7, 2024
Anatara's GaRP granted EU patent
September 20, 2024
GaRP Irritable Bowel Syndrome Clinical Trial Update
August 29, 2024
$626,000 received in R&D Tax Incentive for FY24
August 28, 2024
Appendix 4E & Financial Report 30 June 2024
August 22, 2024
Appendix 4C & Q4 FY24 Activities Report
July 30, 2024
Anatara successful placement for $1.0M
May 1, 2024
Recruitment for Pivotal Phase II IBS Clinical Trial Stage 2
February 29, 2024
Appendix 4D & Half Year Report 31 December 2023
February 28, 2024
Appendix 4C & Q2 FY24 Activities Report
January 23, 2024
Entitlement Offer Results
December 6, 2023
Non-Renounceable Entitlement Offer Booklet
November 13, 2023
Entitlement offer opens and dispatch of Offer Booklet
November 13, 2023
AGM Chair Address
November 9, 2023
GaRP Clinical Trial AGM Presentation
November 9, 2023
Cleansing Notice
November 2, 2023
Anatara launches a partially underwritten Entitlement Offer
November 2, 2023
Appendix 4C & Q1 FY24 Activities Report
October 31, 2023
Webinar Investor Presentation
October 18, 2023
Anatara IBS trial positive secondary endpoint data analysis
October 16, 2023
ANR announces Positive Results from Stage 1 of IBS trial
September 28, 2023
IBS clinical trial Stage 1 patients finalised
August 30, 2023
Appendix 4E & Audited Financial Statements 30 June 2023
August 23, 2023
$923,235 in R&D tax incentive received
August 13, 2023
Appendix 4C & Q4 FY23 Activities Report
July 31, 2023
Anatara Update on GaRP Irritable Bowel Syndrome Trial
June 5, 2023
Appendix 4C & Q3 FY23 Activities Report
April 19, 2023
Anatara Company Update
March 9, 2023